TrialPath
Glioblastoma · Minneapolis

Glioblastoma clinical trials in Minneapolis

6 recruiting glioblastoma studies within range of Minneapolis. Click any trial for full eligibility criteria and contact info.

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Recruiting

The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?

PhasePhase 2
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 38 more
SponsorBlack Diamond Therapeutics, Inc.
▾Tap for details
Apply

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

NCT07831772 · Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
Recruiting

REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead-in phase while receiving standard-of-care therapy off study. Approximately 4 weeks after temozolomide, participants will receive one study-specific 2 Gy fraction of maintenance radiotherapy directed at the post-operative cavity and areas of prior enhancing disease. The study will evaluate the safety and feasibility of delivering maintenance radiotherapy. Blood samples will also be collected before and after maintenance radiotherapy to descriptively compare myeloid-derived suppressor cell frequency.

PhaseNA
TypeInterventional
Age18 Years
WhereMinneapolis, Minnesota, United States
SponsorUniversity of Minnesota
▾Tap for details
Apply

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865 · Astrocytoma, Glioblastoma, Progressive Disease
Recruiting

This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereMinneapolis, Minnesota, United States
SponsorMasonic Cancer Center, University of Minnesota
▾Tap for details

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519 · Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma
Recruiting

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 74 more
SponsorNuvation Bio Inc.
▾Tap for details
Apply

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

NCT04427384 · Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary
Recruiting

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

Phase—
TypeObservational
AgeAny
WherePhoenix, Arizona, United States + 53 more
SponsorGT Medical Technologies, Inc.
▾Tap for details
Apply

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447 · Glioblastoma
Recruiting

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 62 more
SponsorGlobal Coalition for Adaptive Research
▾Tap for details
Apply